Inventor · disambiguated record
Frank S. Menniti
Also filed as: MENNITI FRANK S · MENNITI FRANK SAMUEL · MENNITI Frank
25 granted patents·16 pending applications·290 citations·filing 1995–2025
95Inventor score
Top patents by PatentIndex Score
41 records- 0196US11236104B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2020·Granted Feb 1, 2022·4 cites·28 claims
- 0294US10626122B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Apr 21, 2020·8 cites·16 claims
- 0393US10500205B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Dec 10, 2019·10 cites·22 claims
- 0492US6821985B2Pharmaceutical combinations for the treatment of stroke and traumatic brain injuryPFIZER·Filed 2001·Granted Nov 23, 2004·65 cites·11 claims
- 0592US6667317B2Pharmaceutical combinations for the treatment of stroke and traumatic brain injuryPFIZER·Filed 2001·Granted Dec 23, 2003·60 cites·15 claims
- 0691US12145909B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2BNOVARTIS AG·Filed 2022·Granted Nov 19, 2024·1 cites·21 claims
- 0790US12161624B2Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2BNOVARTIS AG·Filed 2021·Granted Dec 10, 2024·1 cites·20 claims
- 0890US11807650B2NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2022·Granted Nov 7, 2023·1 cites·17 claims
- 0990US10973825B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Apr 13, 2021·6 cites·16 claims
- 1087US11541057B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·1 cites·9 claims
- 1187US11274107B2NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2017·Granted Mar 15, 2022·3 cites·20 claims
- 1283US6136812AMethods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapyPFIZER·Filed 1998·Granted Oct 24, 2000·61 cites·10 claims
- 1381US12358929B2NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2023·Granted Jul 15, 2025·0 cites·14 claims
- 1481US10781174B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2BCADENT THERAPEUTICS INC·Filed 2019·Granted Sep 22, 2020·1 cites·31 claims
- 1579US6258827B1Combinations for the treatment of parkinsonism containing selective NMDA antagonistsPFIZER·Filed 1995·Granted Jul 10, 2001·43 cites·5 claims
- 1676US12162890B2Heteroaromatic NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2021·Granted Dec 10, 2024·0 cites·31 claims
- 1775US6756385B2Imidazole derivativesPFIZER·Filed 2001·Granted Jun 29, 2004·11 cites·12 claims
- 1874US11648253B2Thienopyrimidinone NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2021·Granted May 16, 2023·0 cites·19 claims
- 1974US7078529B2Imidazole derivativesPFIZER·Filed 2004·Granted Jul 18, 2006·8 cites·13 claims
- 2072US6958351B2NMDA NR2B antagonists for treatmentPFIZER·Filed 2001·Granted Oct 25, 2005·5 cites·2 claims
- 2171US11116749B2Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2BCADENT THERAPEUTICS INC·Filed 2018·Granted Sep 14, 2021·0 cites·9 claims
- 2271US10239835B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2BLUC THERAPEUTICS INC·Filed 2015·Granted Mar 26, 2019·1 cites·22 claims
- 2370US2020369610A1N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2bCADENT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2460US2004162294A1Therapeutic use of selective PDE10 inhibitorsPFIZER·Filed 2004·Application pending·0 cites
- 2556US9540324B2Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2BMNEMOSYNE PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·0 cites·18 claims
- 2655US2003018047A1Therapeutic use of selective PDE10 inhibitorsPFIZER·Filed 2002·Application pending·0 cites
- 2754US2004192763A1NMDA NR2B antagonists for treatmentPFIZER·Filed 2004·Application pending·0 cites
- 2854US2025360137A1Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterasesFREEDOM BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 2953US10052306B2Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2BLUC THERAPEUTICS INC·Filed 2016·Granted Aug 21, 2018·0 cites·30 claims
- 3053US2006149066A1Imidazole derivativesPFIZER·Filed 2006·Application pending·0 cites
- 3150US7019016B2NMDA NR2B antagonists for treatmentPFIZER·Filed 2001·Granted Mar 28, 2006·0 cites·2 claims
- 3250US2004162293A1Therapeutic use of selective PDE10 inhibitorsPFIZER·Filed 2004·Application pending·0 cites
- 3347US2003032579A1Therapeutic use of selective PDE10 inhibitorsPFIZER·Filed 2002·Application pending·0 cites
- 3447US2005026236A1PDE 10 cell-based assay and sequencesPFIZER·Filed 2004·Application pending·0 cites
- 3543US2003096323A1PDE10 cell-based assay and sequencesPFIZER·Filed 2002·Application pending·0 cites
- 3643US2003121069A1Disruption of the phosphodiesterase 10 genePFIZER·Filed 2002·Application pending·0 cites
- 3741US2003008806A1Therapeutic use of selective PDE10 inhibitorsPFIZER·Filed 2002·Application pending·0 cites
- 3841US2021181185A1Dendritic cell recruitment from blood to brain in neurodegenerative diseaseMINDIMMUNE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3938US2002072485A1Prophylactic use of N-methyl-D-aspartate (NMDA) antagonistsFiled 2001·Application pending·0 cites
- 4030US2001034345A1Methods of adminstering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapyFiled 1998·Application pending·0 cites
- 4129US2001007872A1Method of treating acute, chronic and/or neuropathic painFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frank S. Menniti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →